Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Dantrium
2. Dantrolene
3. Dantrolene Sodium
4. Sodium, Dantrolene
1. Dantrolene Sodium
2. 14663-23-1
3. Tox21_500424
4. Ccg-221728
5. Ncgc00261109-01
6. Ac-25752
7. D 9175
Molecular Weight | 336.23 g/mol |
---|---|
Molecular Formula | C14H9N4NaO5 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 336.04706368 g/mol |
Monoisotopic Mass | 336.04706368 g/mol |
Topological Polar Surface Area | 110 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 530 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Dantrolene sodium |
Drug Label | The chemical formula of dantrolene sodium is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2, 4-imidazolidinedione sodium salt. It is an orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility incre... |
Active Ingredient | Dantrolene sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg; 25mg; 50mg |
Market Status | Prescription |
Company | Mikah Pharma; Impax Labs |
2 of 2 | |
---|---|
Drug Name | Dantrolene sodium |
Drug Label | The chemical formula of dantrolene sodium is hydrated 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-2, 4-imidazolidinedione sodium salt. It is an orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility incre... |
Active Ingredient | Dantrolene sodium |
Dosage Form | Capsule |
Route | Oral |
Strength | 100mg; 25mg; 50mg |
Market Status | Prescription |
Company | Mikah Pharma; Impax Labs |
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
NDC Package Code : 69575-4036
Start Marketing Date : 2021-10-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (30kg/30kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69988-0029
Start Marketing Date : 2006-09-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 71052-508
Start Marketing Date : 2019-08-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (500g/500g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 67262-2000
Start Marketing Date : 2007-10-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1012
Start Marketing Date : 2002-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49452-2440
Start Marketing Date : 2016-05-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Brand Name: NPJ5008
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Norgine Receives Positive ChMP Opinion for NPJ5008 for Treating Malignant Hyperthermia
Details : NPJ5008 (dantrolene sodium hemiheptahydrate) is a RYR1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of malignant hyperthermia.
Brand Name : NPJ5008
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Details:
The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.
Lead Product(s): Dantrolene
Therapeutic Area: Musculoskeletal Brand Name: Ryanodex
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: JPMorgan Chase Bank
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 24, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Partner/Sponsor/Collaborator : JPMorgan Chase Bank
Deal Size : $160.0 million
Deal Type : Financing
Details : The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulve...
Brand Name : Ryanodex
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 24, 2020
Details:
The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did not sponsor the study.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Brand Name: Ryanodex
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did...
Brand Name : Ryanodex
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2020
Details:
Eagle is working to increase production of RYANODEX in advance of clinical results and to potentially shorten the supply chain lead time if necessary.
Lead Product(s): Dantrolene
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eagle Pharmaceuticals Announces Laboratory Test Results of RYANODEX Against Coronavirus SARS-CoV-2
Details : Eagle is working to increase production of RYANODEX in advance of clinical results and to potentially shorten the supply chain lead time if necessary.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 16, 2020
Details:
Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.
Lead Product(s): Dantrolene
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Diseas...
Details : Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 13, 2020
Details:
Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Lead Product(s): Dantrolene
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Small molecule
Sponsor: Eagle Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 06, 2020
Lead Product(s) : Dantrolene
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Eagle Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, NorthShore University HealthSystem will study Eagle’s RYANODEX® (dantrolene sodium) for traumatic brain injury (TBI) in animal models.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 06, 2020
RLD : No
TE Code :
Brand Name : DANTROLENE SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2016-02-18
Application Number : 205239
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : RYANODEX
Dosage Form : FOR SUSPENSION;INTRAVENOUS
Dosage Strength : 250MG/VIAL
Approval Date : 2014-07-22
Application Number : 205579
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 25MG
Approval Date : 2005-10-24
Application Number : 76686
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2005-10-24
Application Number : 76686
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 100MG
Approval Date : 2005-10-24
Application Number : 76686
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AP
Brand Name : DANTROLENE SODIUM
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2017-06-19
Application Number : 204762
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 25MG
Approval Date : 2005-03-01
Application Number : 76856
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : DANTROLENE SODIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2005-03-01
Application Number : 76856
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AP
Brand Name : REVONTO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 20MG/VIAL
Approval Date : 2007-07-24
Application Number : 78378
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
Brand Name : DANTRIUM
Dosage Form : CAPSULE;ORAL
Dosage Strength : 25MG
Approval Date : 1982-01-01
Application Number : 17443
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?